Download PDF
Thromb Haemost 2009; 101(01): 12-13
DOI: 10.1160/TH08-11-0745
Editorial Focus
Schattauer GmbH

Another view on prasugrel

Andreas Calatzis
1   Haemostasis and Transfusion Medicine Department, University Hospital, Ludwig Maximillians University, Munich, Germany
› Author Affiliations
Further Information

Publication History

Received: 14 November 2008

Accepted: 14 November 2008

Publication Date:
23 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Antithrombotic Trialists’ Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
    CrossrefPubMedGoogle Scholar
  • 2 De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
    CrossrefPubMedGoogle Scholar
  • 4 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 5 Serebruany V, Shalito I, Kopyleva O. Prasugrel development: Claims and achievements. Thromb Haemost 2008; 101: 14-22.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Bhatt DL. Intensifying platelet inhibition--navigating between Scylla and Charybdis. N Engl J Med 2007; 357: 2078-2081.
    CrossrefPubMedGoogle Scholar
  • 7 Serebruany VL. Prasugrel, clopidogrel, and combining Swedish apples with American oranges. Eur Heart J 2006; 27: 1886-1887.
    PubMedGoogle Scholar
  • 8 Serebruany VL, Midei MG, Meilman H. et al. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract 2006; 60: 863-866.
    PubMedGoogle Scholar
  • 9 Serebruany V. Prasugrel versus clopidogrel. N Engl J Med 2008; 358: 1298.
    CrossrefPubMedGoogle Scholar
  • 10 Serebruany VL, Alberts MJ, Hanley DF. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovasc Dis 2008; 26: 93-94.
    CrossrefPubMedGoogle Scholar
  • 11 Serebruany VL. Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?). Am J Cardiol 2008; 101: 1364-1366.
    CrossrefPubMedGoogle Scholar
  • 12 Serebruany VL. Bleeding risks with prasugrel in the TRITON trial: Good news ... bad news. Cardiology 2008; 111: 265-267.
    CrossrefPubMedGoogle Scholar
  • 13 Pasceri V, Patti G, Di Sciascio G. Prasugrel versus clopidogrel. N Engl J Med 2008; 358: 1298-1299.
    CrossrefPubMedGoogle Scholar
  • 14 Ramaraj R. Intensive antiplatelet therapy for reduction of ischaemic events. Lancet 2008; 372: 531.
    CrossrefPubMedGoogle Scholar
  • 15 Wiviott SD, Braunwald E, Murphy SA. et al. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Am J Cardiol 2008; 101: 1367-1370.
    CrossrefPubMedGoogle Scholar
  • 16 Wiviott SD, Braunwald E, Antman EM. Author Reply. N Engl J Med 2008; 358: 1299-1301.
    PubMedGoogle Scholar
  • 17 Wiviott SD, Braunwald E, Murphy SA. et al. Author Reply. Lancet 2008; 372: 532.
    PubMedGoogle Scholar
  • 18 Jernberg T, Wallentin L. Prasugrel, clopidogrel, and combining Swedish apples with American oranges: reply. Eur Heart J 2006; 27: 1887-1888.
    CrossrefPubMedGoogle Scholar